Log In
BCIQ
Print this Print this
 

Prometheus Crohn's Prognostic test

  Manage Alerts
Collapse Summary General Information
Company Nestle S.A.
DescriptionSerogenetic test that combines 6 serologic and 3 genetic markers to create a personalized patient profile
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationAutoimmune, Diagnostic
Indication DetailsPredict the risk of developing disease complications from Crohn's disease and to determine optimal treatment.
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today